SG11202112828SA - Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists - Google Patents

Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists

Info

Publication number
SG11202112828SA
SG11202112828SA SG11202112828SA SG11202112828SA SG11202112828SA SG 11202112828S A SG11202112828S A SG 11202112828SA SG 11202112828S A SG11202112828S A SG 11202112828SA SG 11202112828S A SG11202112828S A SG 11202112828SA SG 11202112828S A SG11202112828S A SG 11202112828SA
Authority
SG
Singapore
Prior art keywords
pyrazole
compositions
methods
imidazole derivatives
orexin antagonists
Prior art date
Application number
SG11202112828SA
Other languages
English (en)
Inventor
Belew Mekonnen
Hemantbhai Patel
Original Assignee
Hager Biosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hager Biosciences Llc filed Critical Hager Biosciences Llc
Publication of SG11202112828SA publication Critical patent/SG11202112828SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11202112828SA 2019-06-04 2020-06-03 Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists SG11202112828SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962856822P 2019-06-04 2019-06-04
PCT/US2020/035851 WO2020247447A1 (en) 2019-06-04 2020-06-03 Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists

Publications (1)

Publication Number Publication Date
SG11202112828SA true SG11202112828SA (en) 2021-12-30

Family

ID=73651984

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202112828SA SG11202112828SA (en) 2019-06-04 2020-06-03 Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists

Country Status (9)

Country Link
US (1) US20220315602A1 (de)
EP (1) EP3972587A4 (de)
JP (1) JP2022534709A (de)
KR (1) KR20220016919A (de)
CN (1) CN114340616A (de)
AU (1) AU2020288559A1 (de)
CA (1) CA3140173A1 (de)
SG (1) SG11202112828SA (de)
WO (1) WO2020247447A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202112827QA (en) * 2019-06-04 2021-12-30 Hager Biosciences Llc Imidazolo derivatives, compositions and methods as orexin antagonists
JP2023508907A (ja) 2019-12-20 2023-03-06 テナヤ セラピューティクス， インコーポレイテッド フルオロアルキル－オキサジアゾールおよびその使用
WO2024050061A2 (en) * 2022-09-01 2024-03-07 Hager Biosciences, Llc Pyrazole and imidazole derivatives as dual orexin and kappa-opioid receptors modulators, composition, methods for treating neurological and psychiatric disorders
CN117169393B (zh) * 2023-11-03 2024-03-19 杭州湃肽生化科技有限公司 一种植物组织中环肽的检测方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1836211B1 (de) * 2004-12-21 2010-03-03 Pfizer Products Inc. Makrolide
US8614242B2 (en) * 2010-10-21 2013-12-24 Bayer Intellectual Property Gmbh 1-(heterocyclic carbonyl)-2-substituted pyrrolidines
EP2730573A4 (de) * 2011-07-05 2014-12-03 Taisho Pharmaceutical Co Ltd Methylpiperidinderivat
EP2771346A4 (de) * 2011-10-25 2015-06-03 Merck Sharp & Dohme Isoxazolopyridin-orexinrezeptorantagonisten
SG11201404738QA (en) * 2012-02-07 2014-10-30 Eolas Therapeutics Inc Substituted prolines / piperidines as orexin receptor antagonists
EP3187497A4 (de) * 2014-08-26 2018-02-07 Takeda Pharmaceutical Company Limited Heterocyclische verbindung
SG11202112827QA (en) * 2019-06-04 2021-12-30 Hager Biosciences Llc Imidazolo derivatives, compositions and methods as orexin antagonists

Also Published As

Publication number Publication date
AU2020288559A1 (en) 2022-01-20
US20220315602A1 (en) 2022-10-06
EP3972587A1 (de) 2022-03-30
WO2020247447A1 (en) 2020-12-10
AU2020288559A8 (en) 2022-02-03
KR20220016919A (ko) 2022-02-10
CN114340616A (zh) 2022-04-12
CA3140173A1 (en) 2020-12-10
JP2022534709A (ja) 2022-08-03
EP3972587A4 (de) 2023-01-18

Similar Documents

Publication Publication Date Title
SG11202112828SA (en) Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists
IL289114A (en) Platforms, preparations and methods for providing treatments
EP3654978A4 (de) Heterocyclische verbindungen als adenosinantagonisten
IL285302A (en) Compounds, preparations and methods
IL268843B (en) History of 6,4,1-trisubstituted-2-alkyl-h1-benzo[d]imidazole as dihydroorotate oxygenase inhibitors
EP3347462A4 (de) Verfahren, zusammensetzungen und verwendung von neuartigen fyn-kinaseinhibitoren
IL280809B (en) New preparations, their use and methods of their creation
EP3911323A4 (de) Heterocyclische verbindungen als adenosinantagonisten
EP3921307C0 (de) Pyrazol derivate
EP3626709A4 (de) Indazolverbindung zur verwendung in der hemmung der kinaseaktivität, zusammensetzung und anwendung davon
EP3371162A4 (de) Makrocyclische spirocarbamat-derivate als faktor-xia-inhibitoren, pharmazeutisch verträgliche zusammensetzungen und deren verwendung
GB201901099D0 (en) Methods, uses and compositions
IL280641A (en) Converted benzimidazoles as PAD4 inhibitors
EP3587403A4 (de) N-substituierte imidazol-carboxylat-verbindung, herstellungsverfahren und verwendung
MX2016014857A (es) Compuestos de [1,2,4]triazol e imidazol sustituidos como fungicidas.
GB202017595D0 (en) Compositions, and methods and uses relating thereto
IL272952A (en) Modified derivatives of 2-aza-bicyclo[3.1.1]-heptane and 2-aza-bicyclo[3.2.1]-octane as orexin receptor blockers
GB2576614B (en) Compositions, uses and methods
GB202017593D0 (en) Compositions and methods and uses relating thereto
IL284762A (en) Heterocyclic compounds as adenosine antagonists
GB201804163D0 (en) Uses, compositions and methods
EP3253761A4 (de) 3,3-difluor-piperidinderivate als nr2b-nmda-rezeptorantagonisten
SG11202112827QA (en) Imidazolo derivatives, compositions and methods as orexin antagonists
IL268565B (en) A history of pyrazoles as bromodomain inhibitors
IL287120A (en) Compounds, preparations and methods